THIRD AMENDMENT TO OEM AGREEMENT

EX-10.4 5 c10593exv10w4.htm THIRD AMENDMENT TO OEM AGREEMENT exv10w4
 

Exhibit 10.4
*Confidential Treatment Requested Under
17 C.F.R. §§ 200.80(b)(4) and 240.24b-2
THIRD AMENDMENT TO
OEM AGREEMENT
This Third Amendment to OEM Agreement, (“Amendment”) is made and entered into as of October 26, 2005 (“Amendment Date”), by and between Akorn-Strides, LLC, a Delaware limited liability company, having a principal place of business at 2500 Millbrook Drive, Buffalo Grove, Illinois 60089-4694, United States of America (“A-S”), and Strides Arcolab Limited, a company organized under the laws of India having a principal place of business at Strides House, Bilekahalli, Bannerghatta Road, Bangalore 560 076, India (“Strides”), (each a “Party” and collectively the “Parties”).
RECITALS
     A. A-S and Strides are parties to that certain OEM Agreement dated September 22, 2004 (“Agreement”) and desire to amend the Agreement to revise the ANDA Schedule, pursuant to the terms and conditions of this Amendment.
NOW, THEREFORE, in consideration of the mutual promises contained herein and other valuable consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:
1.    Definitions. All capitalized terms used herein shall have the same meanings set forth in the Agreement, unless otherwise defined in this Amendment.
2.    Modification of ANDA Schedule. Exhibit B of the Agreement is deleted in its entirety and replaced with Exhibit B attached hereto and fully incorporated herein (“New ANDA Schedule”). The Parties also hereby acknowledge that the schedule, attached hereto as Attachment 1 was a previously adopted, although unsigned schedule originally intended to supercede the original Exhibit B attached to the Agreement but which itself is being superceded pursuant to this Amendment with the New ANDA Schedule.
3.    Counterparts. This Amendment may be executed in several counterparts that together shall be originals and constitute one and the same instrument.
4.    Effect. Except as modified above, the Agreement shall remain in full force and effect in accordance with its specific terms.
IN WITNESS WHEREOF, the parties hereto, through their duly authorized officers, have executed this Amendment as of the Amendment Date.
               
Akorn-Strides, LLC
  Strides Arcolab Limited
 
  
By:
  /s/ Arthur S. Przybyl    By:   /s/ Arun Kumar 
 
           
 
            
Name:
  Arthur S. Przybyl    Name:   Arun Kumar 
 
           
 
            
Its:
  Member Manager    Its:   Executive Vice Chairman & MD 
 
           

           

           

           

Page 1

 

*Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2
EXHIBIT B
ANDA SCHEDULE
                             
 
            Dossier   API Cost   Upgrade   Total Cost of   Status of
Sl. No.   Product Name   STRENGTH   Cost   over 10K   contbn   Dossier   Dossier
                             
1   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
2   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Semi-
Exclusive**
                             
3   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
4   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
5   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
6   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
7   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
8   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
9   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
10   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
11   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
12   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
13   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
14   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
15   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
            [...*...]   [...*...]   [...*...]   [...*...]    
                             
     
                             
                             
NOTE:-PRODUCTS CAN BE DROPPED OR SUBSTITUTED BASED ON JOINT DECISION BY AKORN/STRIDES JV
** Notwithstanding the terms of this Agreement to the contrary, the Parties acknowledge that [...*...] only may be sold by Strides in the Territory in the Exclusive Market to one other entity only in addition to A-S.
* CONFIDENTIAL TREATMENT REQUESTED — This language has been omitted and filed separately with the Securities and Exchange Commission.

 

*Confidential Treatment Requested under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2
ATTACHMENT 1
SUPERCEDED INTERMEDIATE SCHEDULE
                             
                             
            Dossier   API Cost   Upgrade   Total Cost of   Status of
Sl. No.   Product Name   STRENGTH   Cost   over 10K   contbn   Dossier   Dossier
                             
1   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
2   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Semi-Exclusive**
                             
3   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
4   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
5   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
6   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
7   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
8   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
9   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
10   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
11   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
12   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
13   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
14   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
15   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
16   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
17   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
18   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
19   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
20   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   [...*...]   Exclusive
                             
            [...*...]   [...*...]   [...*...]   [...*...]    
                             
                             
                             
                             
NOTE:-PRODUCTS CAN BE DROPPED OR SUBSTITUTED BASED ON JOINT DECISION BY AKORN/STRIDES JV
* CONFIDENTIAL TREATMENT REQUESTED — This language has been omitted and filed separately with the Securities and Exchange Commission.